Caxton Corp Top Holdings and 13F Report (2025) About Caxton CorpInvestment ActivityCaxton Corp has $5.08 million in total holdings as of March 31, 2025.Caxton Corp owns shares of 12 different stocks, but just 2 companies or ETFs make up 80% of its holdings.Approximately 0.73% of the portfolio was purchased this quarter.About 175.00% of the portfolio was sold this quarter.This quarter, Caxton Corp has purchased 15 new stocks and bought additional shares in 1 stock.Caxton Corp sold shares of 1 stock and completely divested from 3 stocks this quarter.Largest Holdings Rezolute $3,825,004SPDR Gold Shares $374,101Berkshire Hathaway $248,816Mind Medicine (MindMed) $199,327BICARA THERAPEUTICS INC $142,562 Largest Purchases this Quarter SPDR Gold Shares 129 shares (about $37.18K) Largest Sales this Quarter Berkshire Hathaway 666 shares (about $354.84K) Sector Allocation Over TimeMap of 500 Largest Holdings ofCaxton Corp Selling Neutral Buying Latest 13F Holdings and Changes Since Previous Quarterly FilingIssuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSectorRZLTRezolute$3,825,0040.0%1,318,96775.3%MedicalGLDSPDR Gold Shares$374,101$37,180 ▲11.0%1,2987.4%FinanceBRK.BBerkshire Hathaway$248,816$354,843 ▼-58.8%4674.9%FinanceMNMDMind Medicine (MindMed)$199,3270.0%34,0733.9%MedicalBICARA THERAPEUTICS INC$142,5620.0%10,9412.8%COMCMPXCompass Therapeutics$82,5840.0%43,4651.6%MedicalLEXEO THERAPEUTICS INC$61,9430.0%17,8511.2%COMKYVERNA THERAPEUTICS INC$44,3540.0%22,9810.9%COMCRDFCardiff Oncology$41,7210.0%13,2870.8%MedicalIKTInhibikase Therapeutics$35,9010.0%16,3930.7%MedicalACETAdicet Bio$13,2030.0%17,4880.3%MedicalCNTXContext Therapeutics$11,2630.0%18,4030.2%MedicalXERSXeris Biopharma$0$6,831,382 ▼-100.0%00.0%MedicalSPYSPDR S&P 500 ETF Trust$0$1,654,494 ▼-100.0%00.0%FinanceGLYCGlycoMimetics$0$50,895 ▼-100.0%00.0%MedicalShowing largest 100 holdings. View all holdings. More Institutional Buying and Selling Information SEC Filings and Trading Data SEC Filings 13F Filings Top 13F Buys Top 13F Sells Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
